These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 19243793)

  • 1. [Eplerenone in resistant hypertension with previous spironolactone intolerance].
    Antonio Costa J; Rodilla E; Pérez-Lahiguera F; María Pascual J
    Med Clin (Barc); 2009 May; 132(19):756-7. PubMed ID: 19243793
    [No Abstract]   [Full Text] [Related]  

  • 2. Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.
    Yugar-Toledo JC; Modolo R; de Faria AP; Moreno H
    Vasc Health Risk Manag; 2017; 13():403-411. PubMed ID: 29081661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
    Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C
    Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ARAs to the RESCUE.
    Kaplan NM
    J Am Soc Hypertens; 2016 Mar; 10(3):187-8. PubMed ID: 27408946
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment considerations with aldosterone receptor antagonists.
    Sica DA; Flack JM
    J Clin Hypertens (Greenwich); 2011 Jan; 13(1):65-9. PubMed ID: 21214724
    [No Abstract]   [Full Text] [Related]  

  • 6. Aldosterone receptor antagonists: effective but often forgotten.
    Maron BA; Leopold JA
    Circulation; 2010 Feb; 121(7):934-9. PubMed ID: 20177008
    [No Abstract]   [Full Text] [Related]  

  • 7. Mineralocorticoid receptor antagonists: their use and differentiation in Japan.
    Sato A
    Hypertens Res; 2013 Mar; 36(3):185-90. PubMed ID: 23171954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
    Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
    Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eplerenone: cardiovascular protection.
    Brown NJ
    Circulation; 2003 May; 107(19):2512-8. PubMed ID: 12756192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eplerenone. Pharmacia.
    Liew D; Martin J; Krum H
    Curr Opin Investig Drugs; 2003 Mar; 4(3):316-22. PubMed ID: 12744223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eplerenone: a review of its use in essential hypertension.
    Croom KF; Perry CM
    Am J Cardiovasc Drugs; 2005; 5(1):51-69. PubMed ID: 15631538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the aldosterone-blocking agents eplerenone and spironolactone.
    Karagiannis A; Athyros VG; Mikhailidis DP
    Clin Cardiol; 2009 Apr; 32(4):230. PubMed ID: 19353701
    [No Abstract]   [Full Text] [Related]  

  • 13. Hypertension, angiotensin II, aldosterone, and race.
    Ben-Yehuda O
    J Am Coll Cardiol; 2003 Apr; 41(7):1156-8. PubMed ID: 12679216
    [No Abstract]   [Full Text] [Related]  

  • 14. Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles.
    Danjuma MI; Mukherjee I; Makaronidis J; Osula S
    Curr Hypertens Rep; 2014 Feb; 16(2):414. PubMed ID: 24407447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does eplerenone have a future in the management of hypertension in Europe?
    Gosse P; Macfadyen RJ
    J Hum Hypertens; 2006 Nov; 20(11):829-32. PubMed ID: 16915301
    [No Abstract]   [Full Text] [Related]  

  • 16. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure.
    Iqbal J; Parviz Y; Pitt B; Newell-Price J; Al-Mohammad A; Zannad F
    Eur J Heart Fail; 2014 Feb; 16(2):143-50. PubMed ID: 24464876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of eplerenone on P-wave signal-averaged electrocardiogram in hypertensive patients with coronary artery disease.
    Kurisu S; Watanabe N; Ikenaga H; Shimonaga T; Higaki T; Iwasaki T; Mitsuba N; Ishibashi K; Dohi Y; Kihara Y
    Int J Cardiol; 2014; 172(1):e180-1. PubMed ID: 24439863
    [No Abstract]   [Full Text] [Related]  

  • 18. Aldosterone receptor blockade: a therapy resurrected.
    Sica DA
    Heart Dis; 2003; 5(2):85-8. PubMed ID: 12713674
    [No Abstract]   [Full Text] [Related]  

  • 19. Eplerenone in the management of resistant hypertension with obstructive sleep apnoea in pregnancy.
    Morton A; Laurie J
    Pregnancy Hypertens; 2017 Jan; 7():54-55. PubMed ID: 28279449
    [No Abstract]   [Full Text] [Related]  

  • 20. Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension.
    Hollenberg NK; Williams GH; Anderson R; Akhras KS; Bittman RM; Krause SL
    Arch Intern Med; 2003 Jul; 163(13):1543-8. PubMed ID: 12860576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.